Journal article
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Abstract
BACKGROUND: Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK2, has shown symptom, spleen, and anaemia benefits in myelofibrosis. We aimed to confirm the differentiated clinical benefits of momelotinib versus the active comparator danazol in JAK-inhibitor-exposed, …
Authors
Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC
Journal
The Lancet, Vol. 401, No. 10373, pp. 269–280
Publisher
Elsevier
Publication Date
1 2023
DOI
10.1016/s0140-6736(22)02036-0
ISSN
0140-6736